Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

81. Sleep-disordered Breathing in Patients with COPD

. 17. Biselli P, Grossman PR, Kirkness JP, Patil SP, Smith PL, Schwartz AR, et al. The effect of increased lung volume in chronic obstructive pulmonary disease on upper airway obstruction during sleep. J Appl Physiol (1985) 2015;119:266–271. 18. Soler X, Diaz-Piedra C, Ries AL. Pulmonary rehabilitation improves sleep quality in chronic lung disease. COPD 2013;10: 156–163. 19. Kohli P, Pinto-Plata V, Divo M, Malhotra A, Harris RS, Lazaar A, et al. Functional capacity, health status, and in?ammatory (...) , the severity of inspiratory and expiratory ?ow limitation, and the presence of hyperin?ation during sleep (e.g., pneumotachography, nasal pressure signaling, and ?ow sensors) in patients with COPD. Introduction Chronic obstructive pulmonary disease (COPD) is a major source of morbidity, mortality, and healthcare costs. It is increasing in epidemic proportions because of the aging population, indoor and outdoor air pollution, historical smoking trends, and other factors (1). Efforts to slow the progression

2018 American Thoracic Society

82. [Nutritional and functional state of patients with chronic obstructive pulmonary disease: effects of oral nutritional supplementation (OFOS study)]. Full Text available with Trip Pro

[Nutritional and functional state of patients with chronic obstructive pulmonary disease: effects of oral nutritional supplementation (OFOS study)]. Weight loss and malnutrition are associated with a worse prognosis of chronic obstructive pulmonary disease (COPD).The main objective of the OFOS study was to assess the efficacy and tolerability of a new nutritional oral formula in adults with COPD with weight loss or malnutrition.Prospective, single-centre, randomized, open-label and controlled (...) trial conducted in Lima (Peru). A total of 99 outpatients of both sexes were included (control [GC]: 49; supplement [GS]: 50), aged from 18 to 80 years old, who had been diagnosed with COPD and that suffered from malnutrition or involuntary weight loss during the last months. Nutritional, functional and quality of life (QoL) variables were evaluated during a three-month intervention.At three months, there was an increase of body mass index (BMI) and fat free mass index (FFMI) significantly higher

2018 Nutricion hospitalaria Controlled trial quality: uncertain

83. Microbial and host immune factors as drivers of COPD Full Text available with Trip Pro

Microbial and host immune factors as drivers of COPD Compartmentalisation of the respiratory tract microbiota in patients with different chronic obstructive pulmonary disease (COPD) severity degrees needs to be systematically investigated. In addition, it is unknown if the inflammatory and emphysematous milieux in patients with COPD are associated with changes in the respiratory tract microbiota and host macrophage gene expression. We performed a cross-sectional study to compare non-COPD (...) controls (n=10) to COPD patients (n=32) with different disease severity degrees. Samples (n=187) were obtained from different sites of the upper and lower respiratory tract. Microbiota analyses were performed by 16S ribosomal RNA gene sequencing and host gene expression analyses by quantitative real-time PCR of distinct markers of bronchoalveolar lavage cells. Overall, the microbial communities of severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 3/4) patients clustered

2018 ERJ open research

84. The Impact of Listening to Music During a High-Intensity Exercise Endurance Test in People With COPD (Abstract)

The Impact of Listening to Music During a High-Intensity Exercise Endurance Test in People With COPD In people with COPD, dyspnea is the primary symptom limiting exercise tolerance. One approach to reducing dyspnea during exercise is through music listening. A constant speed endurance test reflects a high-intensity aerobic exercise training session, but whether listening to music affects endurance time is unknown. This study aimed to determine the effects of listening to music during a constant (...) speed endurance test in COPD.Participants with COPD completed two endurance walk tests, one with and one without listening to self-selected music throughout the test. The primary outcome was the difference in endurance time between the two conditions. Heart rate, percutaneous oxygen saturation, dyspnea, and rate of perceived exertion were measured before and after each test.Nineteen participants (mean [SD]: age, 71 [8] years; FEV1, 47 [19] % predicted) completed the study. Endurance time was greater

2018 EvidenceUpdates

85. Intensified Therapy with Inhaled Corticosteroids and Long-Acting beta2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled T (Abstract)

Intensified Therapy with Inhaled Corticosteroids and Long-Acting beta2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled T The efficacy of intensified combination therapy with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) at the onset of upper respiratory tract infection (URTI) symptoms in chronic obstructive pulmonary disease (COPD (...) analysis, effect size was modified by disease severity, fractional exhaled nitric oxide, and the body mass index-airflow obstruction-dyspnea, and exercise score. Compared with the stable period, evidence of at least one virus was significantly more common at URTI, 10 days after URTI, and at exacerbation.Intensified combination therapy with ICS/LABA for 10 days at URTI onset did not decrease the incidence of any COPD exacerbation but prevented severe exacerbation. Patients with more severe disease had

2018 EvidenceUpdates

86. COPD

COPD Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

87. Self management of patients with mild COPD in primary care: randomised controlled trial. Full Text available with Trip Pro

Self management of patients with mild COPD in primary care: randomised controlled trial. To evaluate the effectiveness of telephone health coaching delivered by a nurse to support self management in a primary care population with mild symptoms of chronic obstructive pulmonary disease (COPD).Multicentre randomised controlled trial.71 general practices in four areas of England.577 patients with Medical Research Council dyspnoea scale scores of 1 or 2, recruited from primary care COPD registers (...) COPD.The primary outcome was health related quality of life at 12 months using the short version of the St George's Respiratory Questionnaire (SGRQ-C).The intervention was delivered with good fidelity: 86% of scheduled calls were delivered; 75% of patients received all four calls. 92% of patients were followed-up at six months and 89% at 12 months. There was no difference in SGRQ-C total score at 12 months (mean difference -1.3, 95% confidence interval -3.6 to 0.9, P=0.23). Compared with patients

2018 BMJ Controlled trial quality: predicted high

88. Intrinsic factors influence self-management participation in COPD: effects on self-efficacy Full Text available with Trip Pro

Intrinsic factors influence self-management participation in COPD: effects on self-efficacy Personal traits should be addressed before offering self-management programmes to patients with COPD http://ow.ly/DtNh30k1A15.

2018 ERJ open research

89. Influence of dietary nitrate supplementation on lung function and exercise gas exchange in COPD patients. Full Text available with Trip Pro

Influence of dietary nitrate supplementation on lung function and exercise gas exchange in COPD patients. During exercise as pulmonary blood flow rises, pulmonary capillary blood volume increases and gas exchange surface area expands through distention and recruitment. We have previously demonstrated that pulmonary capillary recruitment is limited in COPD patients with poorer exercise tolerance. Hypoxia and endothelial dysfunction lead to pulmonary vascular dysregulation possibly in part (...) related to nitric oxide related pathways.To determine if increasing dietary nitrate might influence lung surface area for gas exchange and subsequently impact exercise performance.Subjects had stable, medically treated COPD (n = 25), gave informed consent, filled out the St George Respiratory Questionnaire (SGRQ), had a baseline blood draw for Hgb, performed spirometry, and had exhaled nitric oxide (exNO) measured. Then they performed the intra-breath (IB) technique for lung diffusing capacity

2018 Nitric oxide : biology and chemistry Controlled trial quality: uncertain

90. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow)

with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Ov Overview erview This evidence summary discusses 3 randomised controlled trials (TRILOGY, TRINITY and TRIBUTE) looking at the safety and efficacy of beclometasone/formoterol/glycopyrronium in people with COPD with severe or very severe airflow limitation, symptoms despite treatment and a history of exacerbations. © NICE 2018. All rights reserved. Subject to Notice (...) , quality assured and approved for publication. Expert advisers Professor Peter Calverley, professor of respiratory medicine, University of Liverpool. Dr Anastasios Lekkas, consultant respiratory physician, University Hospital Southampton NHS Foundation Trust. Dr Sarah Scrivener, consultant respiratory physician, Portsmouth Hospitals NHS Trust. Professor Jadwiga Wedzicha, professor of respiratory medicine, Imperial College London. Chronic obstructive pulmonary disease: beclometasone, formoterol

2018 National Institute for Health and Clinical Excellence - Advice

91. Tai Chi and Pulmonary Rehabilitation Compared for Treatment-Naive Patients With COPD: A Randomized Controlled Trial Full Text available with Trip Pro

Tai Chi and Pulmonary Rehabilitation Compared for Treatment-Naive Patients With COPD: A Randomized Controlled Trial In COPD, functional status is improved by pulmonary rehabilitation (PR) but requires specific facilities. Tai Chi, which combines psychological treatment and physical exercise and requires no special equipment, is widely practiced in China and is becoming increasingly popular in the rest of the world. We hypothesized that Tai Chi is equivalent (ie, difference less than ±4 St (...) . George's Respiratory Questionnaire [SGRQ] points) to PR.A total of 120 patients (mean FEV1, 1.11 ± 0.42 L; 43.6% predicted) bronchodilator-naive patients were studied. Two weeks after starting indacaterol 150 μg once daily, they randomly received either standard PR thrice weekly or group Tai Chi five times weekly, for 12 weeks. The primary end point was change in SGRQ prior to and following the exercise intervention; measurements were also made 12 weeks after the end of the intervention.The between

2018 EvidenceUpdates

92. Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation Full Text available with Trip Pro

Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation Previous models of Hospital at Home (HAH) for COPD exacerbation (ECOPD) were limited by the lack of a reliable prognostic score to guide patient selection. Approximately 50% of hospitalised patients have a low mortality risk by DECAF, thus are potentially suitable.In a non-inferiority randomised controlled trial, 118 patients admitted with a low-risk ECOPD (DECAF 0 (...) or 1) were recruited to HAH or usual care (UC). The primary outcome was health and social costs at 90 days.Mean 90-day costs were £1016 lower in HAH, but the one-sided 95% CI crossed the non-inferiority limit of £150 (CI -2343 to 312). Savings were primarily due to reduced hospital bed days: HAH=1 (IQR 1-7), UC=5 (IQR 2-12) (P=0.001). Length of stay during the index admission in UC was only 3 days, which was 2 days shorter than expected. Based on quality-adjusted life years, the probability of HAH

2018 EvidenceUpdates

93. VIDAvision for lung volume analysis in emphysema

, parenchyma and a range of CT biomarkers – such as fissure integrity – and analytics. This visualisation can then be used to assess a patient's suitability for therapies. VIDAvision can be used to do a range of analyses including: airway mapping for bronchoscopy biopsy lung cancer resection precision reports lung density air trapping information in people with chronic obstructive pulmonary disease (COPD) and asthma lung volume analysis to support treatment selection planning for endobronchial lung volume (...) and few patients in the UK receive bronchoscopy to assess whether ELVR surgery is needed. The following NICE guidance has been identified as being relevant to this care pathway: Chronic obstructive pulmonary disease in over 16s: diagnosis and management VIDAvision for lung volume analysis in emphysema (MIB148) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 10Lung volume reduction surgery for advanced emphysema

2018 National Institute for Health and Clinical Excellence - Advice

94. Beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium (Riarify - (previously CHF 5993 Chiesi Farmaceutici S.p.A.)) - Chronic Obstructive Pulmonary Disease

Clinical Endpoint Committee CHMP Committee for Medicinal Products for Human Use CI confidence interval COPD chronic obstructive pulmonary disease CPRD Clinical Practice Research Database CRF/eCRF case report form/electronic case report form CSR clinical study report CT computed tomography CV cardiovascular ECG electrocardiogram EMA European Medicines Agency EPAR European Public Assessment Report ERS European Respiratory Society EXACT-RS Exacerbations of Chronic Pulmonary Disease Tool EXT Extension (...) the centralised procedure under Article 3 (2)(b) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 18 May 2017. The eligibility to the centralised procedure under Article 3(2)(b) of Regulation (EC) No 726/2004 was based on demonstration of interest of patients at Community level. The applicant applied for the following indication: Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who

2018 European Medicines Agency - EPARs

95. Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trydonis) - COPD, Chronic Obstructive Pulmonary Disease

for Medicinal Products for Human Use CI confidence interval COPD chronic obstructive pulmonary disease CPRD Clinical Practice Research Database CRF/eCRF case report form/electronic case report form CSR clinical study report CT computed tomography CV cardiovascular ECG electrocardiogram EMA European Medicines Agency EPAR European Public Assessment Report ERS European Respiratory Society EXACT-RS Exacerbations of Chronic Pulmonary Disease Tool EXT Extension (Population) FDA Food and Drug Administration FEV 1 (...) Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trydonis) - COPD, Chronic Obstructive Pulmonary Disease 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 22 February 2018 EMA/155337/2018 Committee

2018 European Medicines Agency - EPARs

96. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)

and current guidance The NICE guideline on chronic obstructive pulmonary disease (COPD) is currently being updated (expected publication date November 2018). The current COPD guideline states that COPD is characterised by airflow obstruction that is usually progressive and not fully reversible, and is predominantly caused by smoking. COPD causes symptoms, disability and impaired quality of life, which may respond to pharmacological and other therapies that have limited or no measurable impact (...) chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA (summary of product characteristics). Ov Overview erview This evidence summary discusses 2 randomised controlled trials (RCTs) looking at the safety and efficacy of fluticasone furoate/umeclidinium/vilanterol (an ICS/LAMA and LABA combination inhaler) in people with COPD who were symptomatic despite regular maintenance treatment and who either had a history, or were at risk

2018 National Institute for Health and Clinical Excellence - Advice

97. Core IM: Mind the Gap on Steriods in COPD

with COPD exacerbations do not return to baseline within 3 months of an exacerbation. Many thanks to Dr. Melissa Lesko, Pulmonologists at NYU, for peer reviewing this episode. References (2:44 to end) Vogelmeier CF et al. “Global Strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary.” Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. (3:04) Wedzicha JA “Oral corticosteroids for exacerbations of chronic obstructive pulmonary (...) Initiative for Chronic Obstructive Lung Disease) define a COPD exacerbation? (2:44) What outcomes do steroids actually improve in treating a COPD exacerbation? (5:08) What is the evidence behind a 5 day steroid “burst”? (7:20) Are IV steroids more powerful than PO? (9:00) Subscribe to CORE IM on any podcast app! Follow us on Facebook || Twitter || Instagram . Please give any feedback at . Show Notes A moderate to severe COPD exacerbation is defined as at least 2 of the 3 cardinal symptoms : change

2018 Clinical Correlations

98. Narrative medicine educational project to improve the care of patients with chronic obstructive pulmonary disease Full Text available with Trip Pro

Narrative medicine educational project to improve the care of patients with chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is characterised by a progressive loss of pulmonary function. Often patients do not adhere to inhaled therapies and this leads clinicians to switch treatments in order to improve control of the symptoms. Narrative medicine is a useful approach that helps healthcare professionals to think over the doctor-patient relationship and how (...) patients live with their disease. The aim of this training project was to teach pulmonologists the basics of narrative medicine: to carefully listen to patients and to practice reflective writing in their relationship with them. Training on narrative medicine and parallel charts was provided through a webinar and a weekly newsletter. Across 362 narratives, written by 74 Italian pulmonologists, 92% of patients had activity limitations at their first visit. The main factor influencing the effectiveness

2018 ERJ open research

99. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Full Text available with Trip Pro

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double (...) -blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg using the Ellipta inhaler with twice-daily budesonide/formoterol (BUD/FOR) 400/12 µg using the Turbuhaler. Subgroup analyses of forced expiratory volume in 1 s (FEV1), St George's Respiratory Questionnaire (SGRQ) Total score and exacerbation rates were carried out. Subgroups were defined by COPD medication at screening (ICS+LABA, BUD+FOR, ICS+LABA+LAMA, LAMA alone, tiotropium alone

2018 ERJ open research Controlled trial quality: predicted high

100. Inspiratory muscle training does not improve clinical outcomes in 3-week COPD rehabilitation: results from a randomised controlled trial Full Text available with Trip Pro

Inspiratory muscle training does not improve clinical outcomes in 3-week COPD rehabilitation: results from a randomised controlled trial The value of inspiratory muscle training (IMT) in pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD) is unclear. The RIMTCORE (Routine Inspiratory Muscle Training within COPD Rehabilitation) randomised controlled trial examined the effectiveness of IMT added to pulmonary rehabilitation.In total, 611 COPD patients (Global Initiative (...) for Chronic Obstructive Lung Disease stage II-IV) received a 3-week inpatient pulmonary rehabilitation, of which 602 patients were included in the intention-to-treat analyses. The intervention group (n=300) received highly intensive IMT and the control group (n=302) received sham IMT. The primary outcome was maximal inspiratory pressure (PImax). The secondary outcomes were 6-min walk distance, dyspnoea, quality of life and lung function. Outcomes were assessed pre- and post-pulmonary rehabilitation

2018 EvidenceUpdates